Global Generative AI In Clinical Trials Market 2026 – 2035

The global Generative AI in Clinical Trials market size was estimated at USD 0.81 billion in 2026 and is projected to reach USD 1.86 billion by 2035 with a compound annual growth rate (CAGR) of 9.63% between the forecast period (2026-2035). The market for North America captured a share of about 41% in the global market size in 2025, due to quick adoption of generative AI technology by leading pharmaceutical, biotechnology, contract research organizations, and educational research institutions.

North America dominates the market with a presence of a well-developed clinical research ecosystem, ample funding in artificial intelligence and drug discovery and the proliferation of electronic health records (EHR). Increased usage of generative AI for clinical trial protocol design, patient recruitment, clinical document generation, clinical site selection, submission for regulatory agencies and clinical trial decentralization.

A favorable regulatory environment for innovation, increasing collaboration between technology vendors and the pharmaceutical sector, and increasing funding towards AI-enabled clinical research tools are expected to boost market growth in this region.

Market Highlight

• The Cloud segment held a share of around 66.12% in the global Generative AI in Clinical Trials market in 2025, owing to the increasing use of scalable cloud infrastructure, deployment of AI models and seamless integration of the Cloud with CTMS, EDC, EHR, and real-world evidence platforms.

• Within the technology category, Large Language Models (LLMs) accounted for almost 31.48% of the total, as they enable automation for protocol generation, patient eligibility screening, medical writing, regulatory documentation and clinical data analysis.

• With the growing adoption of generative AI in patient recruitment, clinical trial monitoring, protocol optimization, and regulatory submissions in large clinical trials, the clinical trial phase segment was driven by Phase III, which represented around 37.26% of the market.

• The North America was the dominant region in the global Generative AI in Clinical Trials market during 2025, owing to the presence of well-developed clinical research infrastructure, robust pharmaceutical and biotechnology sector, early adoption of AI, and high investments in digital clinical trial technologies.

Significant Growth Factors

• Increasing Uptake of AI for Clinical Trial Design and Patient Recruitment: Pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are increasing their use of generative AI to refine protocol design, speed up patient recruitment, and boost trial efficiency. Sophisticated AI systems, encompassing LLMs, NLP, and predictive modeling capabilities, are utilized to perform quick analysis of large datasets, such as electronic health records (EHRs), clinical research studies, genomic data, and RWE, to identify potential candidates and adapt the protocol. These models help to refine the inclusion/exclusion criteria for participants and also decrease the incidence of protocol amendments as they are being conducted. As more companies explore adaptive and decentralized trials, the use of generative AI for faster, more effective clinical planning and improved diversity of study participants will further gain momentum.

• Rise of Generative AI across Clinical Operations and Drug Development: Investment in AI-enabled drug development, DCTs, and digital clinical research solutions has fueled market expansion for generative AI in clinical trials. Organizations are harnessing the potential of generative AI to automate several routine but critical tasks involved in clinical operations such as preparing regulatory submissions, adverse event reports, site selections, medical writing, clinical documentation, and data analysis. The advent of multimodal AI and other recent developments such as advances in cloud computing, predictive analytics, and the growth of generative AI technologies and collaborations among drug development and CRO partners are expected to contribute to sustained market growth in the coming years.

Drivers Impact Analysis

Restraints Impact Analysis

What are the major advances? Changing the generative AI in the clinical trials market today?

Generative AI and LLMs are Revolutionizing Clinical Trial Design & Protocol Development

The way clinical trials are designed and executed is shifting significantly due to generative AI and large language models (LLMs). Generative AI and LLMs automate clinical trial protocol creation, help optimize endpoints andeligibilitycriteria, and are increasingly using a vast trove of data from scientific publications, historic clinical trials, regulatory guidance and real-world evidence (RWE) to design smarter protocols with fewer amendments and improved operational efficiencies.

AI -powered clinical trial design reduces trial development time, increases protocol feasibility and contributes to more patient-centric designs, all of which helpspharmaceuticalCompaniesand Contract Research Organizations (CROs) reduce complexity, decrease costs and improve efficiencies when undertaking clinical development programs.

AI-Powered Patient Recruitment and Clinical Trial Analytics Help Optimize Trial Operations

By leveraging advanced predictive analytics and intelligent data processing, AI is accelerating every step of clinical trials, frompatient recruitmentto site selection and trial operations. By connecting EHR data, genomics, insurance claims, wearable devices and RWE, the bestAI Platforms identify, match and screen eligible patients, predict the enrollment rates of individual sites and monitor Investigator Site performance in real time.

This intelligent data analysis with machine learning capabilities forecasts recruitment bottlenecks, helps manage patient diversity, predicts trial dropout rates and guides adaptive trials, leading to rapid and efficient patient recruitment, robust trial operations, and a higher chance of trial success.

Intelligent Data Management, Regulatory Automation, and DCT Support Drive Digital Transformation

The acceleration of Generative AI, natural language processing (NLP), and cloud-based clinical trial systems is bringing about new, intelligent solutions for clinical data management, regulatory documentation and Decentralized Clinical Trial (DCT) operations. With AI-enabled solutions automatically assisting medical writing, adverse event reporting, Clinical Study Report (CSR) generation, regulatory filings and data quality monitoring with regulatory consistency and compliance standards, researchers can save time and reduce manual administrative effort. Integration with electronic data capture (EDC) systems, clinical trial management systems (CTMS), and remote patient monitoring technologies provides visibility and insight into clinical trials in real-time and supports the growing ecosystem of DCTs globally.

Category Wise Insights

By Deployment Mode

Why the Cloud Sector is Leading the Way in the Market

The Cloud segment is expected to be the leading deployment mode in the Global Generative AI in Clinical Trials Market during the forecast period, as users are increasingly looking to scalable computing infrastructure, GPU-accelerated AI training, and collaborative clinical research environments. Pharma, biotechnology organizations and contract research organizations (CROs) can utilize cloud-based platforms to effectively build, deploy and utilize generative AI models for protocol design, patient recruitment, data analysis for clinical trials and regulatory documentation.

The seamless integration with electronic health records (EHRs), clinical trial management systems (CTMS), electronic data capture (EDC) platforms, and real-world evidence (RWE) databases further reinforces the acceptance of cloud adoption. The cost of infrastructure, quick scalability, and Software-as-a-Service (SaaS) delivery models continue to support cloud deployment as the preferred deployment model.

By Technology

What is the Driver of the Market? Large Language Models (LLMs)?

In 2025, the technology share in the clinical trials market was dominated by Large Language Models (LLMs) accounting for just about 31.48% of the total market, as they are key to automating clinical trial documentation, protocol generation, medical writing, patient eligibility assessment, and regulatory submissions. The LLMs can process large amounts of structured and unstructured clinical data, scientific literature, clinical guidelines, and regulatory documentation to provide precise and contextually relevant insights, enhancing the efficiency and easing the burden of manual tasks in clinical trials.

The LLMs have emerged as the go-to technology for streamlining clinical research workflows due to their capabilities in natural language understanding, knowledge synthesis, and conversational AI. Adoption of domain-specific AI tools is further propelled by continuous evolution of LLM capabilities, retrieval-augmented generation (RAG), and multimodal AI, within the life sciences sector.

By Phase of Clinical Trial

What is driving the success of Phase III?

The size and complexity, along with its cost, of late-stage clinical trials drive the growth of the Phase III segment in the global Generative AI in Clinical Trials market, accounting for around 37.26% during 2025. The clinical, operational, and regulatory data generated in the course of conducting Phase III trials are often large in volume and require complex management and analysis of data through AI.

From optimizing the patient recruitment and predicting patient enrollment outcomes to automating clinical documentation and tracking trial performance to assisting with adaptive trial designs and regulatory reporting, generative AI is making significant strides in these areas and more. Phase III is the biggest use case for generative AI in clinical research as pharma firms strive to better achieve trial success, shorten development timelines and speed up regulatory approvals.

Report Scope

Regional Analysis

How Big is the North America Market Size?

North America Generative ai in clinical trials market size is forecast to reach USD 0.34 Billion by 2025 and is expected to reach around USD 0.83 billion by 2035 with a CAGR of 9.45% from 2026 to 2035.

Why North America is Leading the Market in 2025?

In 2025, North America will likely dominate the global generative AI in clinical trials market, owing to its well-established clinical research infrastructure, robust pharmaceutical and biotechnology sector, and early adoption of AI in the drug development process. The United States is currently the region's leader in investing in AI-powered clinical trial platforms, decentralized clinical trials (DCTs), electronic health records (EHRs), and real-world evidence (RWE) analytics.

Now, major pharmaceutical firms, contract research organizations (CROs), and technology vendors are turning to generative AI to create protocols, recruit patients, fill out clinical documentation, submit to regulators, and monitor clinical trials. The Generative AI in Clinical Trials market is expected to witness the fastest growth from North America, owing to robust regulatory support, increased spending on R&D, and increasing collaboration between the AI companies, life sciences companies, and academic medical centers.

Why is Asia Pacific an Important and Growing Market?

Asia Pacific is projected to have the highest CAGR in the generative AI in clinical trials market by 2035, owing to the growing pharmaceutical research, rising clinical trial activities, and quick digitalization of healthcare. Countries such as China, Japan, India, South Korea, Singapore, and Australia are investing significant resources in a range of initiatives to modernize clinical research, including in the areas of AI, cloud computing, healthcare data infrastructure, and precision medicine.

The market is expected to witness significant opportunities driven by the growing incidence of global CROs, the rising number of multinational clinical trials, the rising adoption of decentralized clinical trials, and the rising uses of AI-powered patient recruitment and data analytics. The growing investments in digital healthcare innovation and the government support for the same are contributing to the regional market growth.

What makes Europe a strategically important market?

The Generative AI for Clinical Trials market in Europe is technology-intensive, leveraging the well-established pharmaceutical sector, mature clinical research ecosystem, and the growing adoption of AI solutions in the European healthcare sector. Germany, UK, France, Italy, Spain, Switzerland, and the Netherlands are all committed to innovating in their respective areas of drug development, clinical trial research institutes and digital health transformation through investments in generative AI.

These generative AI technologies are already used globally for protocol optimization, authoring regulatory submissions, patient recruitment and result interpretation to improve the research process. With a strengthening European AI regulatory roadmap, a supportive funding landscape and ongoing partnerships and collaboration in the field of clinical research, Europe is gaining traction in the market.

What is driving the growth in Latin America?

The region is now a growing market for the pharmaceutical industry because of the increase in clinical trial activities undertaken by more pharmaceutical firms and CROs. The quick snapshot of the state of clinical research around the world indicates those countries that are investing in their healthcare system's infrastructure, wider uptake of digital health and regulatory modernization to support the development of clinical research.

Demand for generative AI solutions is accelerating as more individuals take part in clinical trials globally, more clinical systems are becoming electronic, and investments in AI-powered research technologies continue to increase. Continued partnerships between international pharmaceutical companies, research centers and regional healthcare providers will be expected to drive continued market growth.

Why is the Middle East & Africa an emerging market?

The Middle East & Africa Generative AI in Clinical Trials market is gradually expanding due to the increasing focus of governments across the region on digitalization in healthcare, biomedical research, and innovation in the life sciences sector. Investments in precision medicine, AI technologies, electronic health systems, and digital clinical trial capabilities are part of the initiatives being undertaken by countries like Saudi Arabia, the United Arab Emirates, Qatar, South Africa, and Israel to boost clinical research infrastructure.

The generative AI is being widely used by healthcare organizations and research institutions to recruit patients, manage clinical trial data, prepare regulatory paperwork, and conduct decentralized clinical trials. Adoption is still in its infancy relative to the developed nations, but it will see substantial growth opportunities in the future driven by increases in the pharmaceutical investment, digital infrastructure, and government healthcare programs.

Key Market Players

• IQVIA Holdings Inc.

• Medidata Solutions (Dassault Systèmes)

• Oracle Health Sciences (Oracle Corporation)

• Veeva Systems Inc.

• Microsoft Corporation

• Google LLC (Google Cloud)

• Amazon Web Services (AWS)

• NVIDIA Corporation

• Tempus AI Inc.

• Unlearn AI Inc.

• Saama Technologies LLC

• Insilico Medicine

• PathAI Inc.

• Owkin Inc.

• ConcertAI LLC

• Others

Key Developments

Producers are making progress towards commercialization of bio-isobutanol as well as new product portfolios and a rise in global demand within coatings, paints, and also gas usage sectors. Some industry growths:

• June 2025 – IQVIA improved its AI powered medical research ability as the business improved the generative AI features of its medical trial style, patient enrolment, and also study operations software programs to help pharma business as well as CROs speed up medical trial duration, increase protocol efficiency, as well as optimize client enlistment rates.

• April 2025 – Medidata Options (Dassault Systèmes) introduced new generative AI capabilities that allow the automating of protocol creation, medical record creating, medical authoring, and also medical trial information analytics via their medical trial software.

The Generative Ai In Clinical Trials Market is segmented as follows:

By Deployment Mode

• Cloud

• On-Premises

• Hybrid

By Technology

• Generative AI

• Large Language Models (LLMs)

• Natural Language Processing (NLP)

• Machine Learning & Deep Learning

• Predictive Analytics

• Computer Vision

• Retrieval-Augmented Generation (RAG)

• Knowledge Graphs

• Multimodal AI

By Clinical Trial Phase

• Phase I

• Phase II

• Phase III

• Phase IV

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America